Because sacubitril/valsartan improved outcomes and reduced NT-proBNP in adult patients in PARADIGM-HF, this effect on NT-proBNP was considered a reasonable basis to infer improved cardiovascular outcomes in pediatric patients. This evidence concerns the gene NPPB and hydrops fetalis.